DNA The DNA Core located in the Eckstein Medical Research Building adjacent to the Holden Cancer Research Laboratories supports research performed by investigators in all HCCC programs. It provides a broad spectrum of services and resources designed to make the state-of-the-art techniques used in DNA sequence and transcript analysis readily available to the University of lowa research community. These services and resources include: 1) DNA sequencing, 2) custom oligonucleotides, 3) DNA microarrays using both the Affymetrix GeneChip system and the custom spotted array using the microscope slide format, 4) real-time PCR, 5) molecular biology computing, and 6) genome sequencing using next generation sequencing technologies. It is the aim of the DNA Core to provide high quality services to HCCC members with a rapid turnaround and support these services with well-trained personnel. The core also continues to evaluate andupdate their services so they remain cutting-edge and provides new services, as needed, to continue to meet the needs of HCCC investigators. In 2009, the DNA Core provided services to 82 HCCC members with peer reviewed funding.

Public Health Relevance

The DNA Core is highly cancer relevant. The services it provides, including state-of-the-art DNA sequencing, production of custom oligonucleotides, and microarray analysis, are necessary tools for the conduct of modern molecular cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA086862-11
Application #
8340092
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-08-19
Project End
2016-03-31
Budget Start
2011-08-19
Budget End
2012-03-31
Support Year
11
Fiscal Year
2011
Total Cost
$82,688
Indirect Cost
Name
University of Iowa
Department
Type
DUNS #
062761671
City
Iowa City
State
IA
Country
United States
Zip Code
52242
Kim, Yusung; Cabel, Katherine; Sun, Wenqing (2018) Does the apex optimization line matter for single-channel vaginal cylinder brachytherapy planning? J Appl Clin Med Phys 19:307-312
Hagan, Teresa L; Gilbertson-White, Stephanie; Cohen, Susan M et al. (2018) Symptom Burden and Self-Advocacy: Exploring the Relationship Among Female Cancer Survivors?. Clin J Oncol Nurs 22:E23-E30
Chesney, Jason; Puzanov, Igor; Collichio, Frances et al. (2018) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol 36:1658-1667
Brooks, Jennifer D; Comen, Elizabeth A; Reiner, Anne S et al. (2018) CYP2D6 phenotype, tamoxifen, and risk of contralateral breast cancer in the WECARE Study. Breast Cancer Res 20:149
Chioreso, Catherine; Del Vecchio, Natalie; Schweizer, Marin L et al. (2018) Association Between Hospital and Surgeon Volume and Rectal Cancer Surgery Outcomes in Patients With Rectal Cancer Treated Since 2000: Systematic Literature Review and Meta-analysis. Dis Colon Rectum 61:1320-1332
Musselman, Catherine A; Kutateladze, Tatiana G (2018) A histone reader becomes the readout. J Biol Chem 293:7486-7487
Merritt, Nicole M; Fullenkamp, Colleen A; Hall, Sarah L et al. (2018) A comprehensive evaluation of Hippo pathway silencing in sarcomas. Oncotarget 9:31620-31636
Haskins, Cole B; McDowell, Bradley D; Carnahan, Ryan M et al. (2018) Impact of preexisting mental illness on breast cancer endocrine therapy adherence. Breast Cancer Res Treat :
Daneshmand, Siamak; Patel, Sanjay; Lotan, Yair et al. (2018) Efficacy and Safety of Blue Light Flexible Cystoscopy with Hexaminolevulinate in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multicenter Study. J Urol 199:1158-1165
Borcherding, Nicholas; Kolb, Ryan; Gullicksrud, Jodi et al. (2018) Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. J Mol Biol 430:2014-2029

Showing the most recent 10 out of 1080 publications